1
|
Ahrari S, Zaragori T, Zinsz A, Oster J, Imbert L, Verger A. Application of PET imaging delta radiomics for predicting progression-free survival in rare high-grade glioma. Sci Rep 2024; 14:3256. [PMID: 38332004 PMCID: PMC10853227 DOI: 10.1038/s41598-024-53693-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2023] [Accepted: 02/03/2024] [Indexed: 02/10/2024] Open
Abstract
This study assesses the feasibility of using a sample-efficient model to investigate radiomics changes over time for predicting progression-free survival in rare diseases. Eighteen high-grade glioma patients underwent two L-3,4-dihydroxy-6-[18F]-fluoro-phenylalanine positron emission tomography (PET) dynamic scans: the first during treatment and the second at temozolomide chemotherapy discontinuation. Radiomics features from static/dynamic parametric images, alongside conventional features, were extracted. After excluding highly correlated features, 16 different models were trained by combining various feature selection methods and time-to-event survival algorithms. Performance was assessed using cross-validation. To evaluate model robustness, an additional dataset including 35 patients with a single PET scan at therapy discontinuation was used. Model performance was compared with a strategy extracting informative features from the set of 35 patients and applying them to the 18 patients with 2 PET scans. Delta-absolute radiomics achieved the highest performance when the pipeline was directly applied to the 18-patient subset (support vector machine (SVM) and recursive feature elimination (RFE): C-index = 0.783 [0.744-0.818]). This result remained consistent when transferring informative features from 35 patients (SVM + RFE: C-index = 0.751 [0.716-0.784], p = 0.06). In addition, it significantly outperformed delta-absolute conventional (C-index = 0.584 [0.548-0.620], p < 0.001) and single-time-point radiomics features (C-index = 0.546 [0.512-0.580], p < 0.001), highlighting the considerable potential of delta radiomics in rare cancer cohorts.
Collapse
Affiliation(s)
- Shamimeh Ahrari
- Imagerie Adaptative Diagnostique et Interventionnelle, Institut National de la Santé et de la Recherche Médicale U1254, Université de Lorraine, 54000, Nancy, France
- Nancyclotep Imaging Platform, Université de Lorraine, 54000, Nancy, France
| | - Timothée Zaragori
- Imagerie Adaptative Diagnostique et Interventionnelle, Institut National de la Santé et de la Recherche Médicale U1254, Université de Lorraine, 54000, Nancy, France
- Nancyclotep Imaging Platform, Université de Lorraine, 54000, Nancy, France
| | - Adeline Zinsz
- Department of Nuclear Medicine, Centre Hospitalier Régional Universitaire de Nancy, 54000, Nancy, France
| | - Julien Oster
- Imagerie Adaptative Diagnostique et Interventionnelle, Institut National de la Santé et de la Recherche Médicale U1254, Université de Lorraine, 54000, Nancy, France
| | - Laetitia Imbert
- Imagerie Adaptative Diagnostique et Interventionnelle, Institut National de la Santé et de la Recherche Médicale U1254, Université de Lorraine, 54000, Nancy, France
- Nancyclotep Imaging Platform, Université de Lorraine, 54000, Nancy, France
- Department of Nuclear Medicine, Centre Hospitalier Régional Universitaire de Nancy, 54000, Nancy, France
| | - Antoine Verger
- Imagerie Adaptative Diagnostique et Interventionnelle, Institut National de la Santé et de la Recherche Médicale U1254, Université de Lorraine, 54000, Nancy, France.
- Nancyclotep Imaging Platform, Université de Lorraine, 54000, Nancy, France.
- Department of Nuclear Medicine, Centre Hospitalier Régional Universitaire de Nancy, 54000, Nancy, France.
| |
Collapse
|
2
|
Wang C, Liu C, Chang Y, Lafata K, Cui Y, Zhang J, Sheng Y, Mowery Y, Brizel D, Yin FF. Dose-Distribution-Driven PET Image-Based Outcome Prediction (DDD-PIOP): A Deep Learning Study for Oropharyngeal Cancer IMRT Application. Front Oncol 2020; 10:1592. [PMID: 33014811 PMCID: PMC7461989 DOI: 10.3389/fonc.2020.01592] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2020] [Accepted: 07/23/2020] [Indexed: 12/31/2022] Open
Abstract
Purpose To develop a deep learning-based AI agent, DDD-PIOP (Dose-Distribution-Driven PET Image Outcome Prediction), for predicting 18FDG-PET image outcomes of oropharyngeal cancer (OPC) in response to intensity-modulated radiation therapy (IMRT). Methods DDD-PIOP uses pre-radiotherapy 18FDG-PET/CT images and the planned spatial dose distribution as the inputs, and it predicts the 18FDG-PET image outcomes in response to the planned IMRT delivery. This AI agent centralizes a customized convolutional neural network (CNN) as a deep learning approach, and it incorporates a few designs to enhance prediction accuracy. 66 OPC patients who received IMRT treatment on a sequential boost regime (2 Gy/daily fraction) were studied for DDD-PIOP development. 61 patients were used for AI agent training/validation, and the remaining five were used as independent tests. To evaluate the developed AI agent’s performance, the predicted mean standardized uptake values (SUVs) of gross tumor volume (GTV) and clinical target volume (CTV) were compared with the ground truth values. Overall SUV distribution accuracy was evaluated by gamma test passing rates under different criteria. Results The developed DDD-PIOP successfully generated 18FDG-PET image outcome predictions for five test patients. The predicted mean SUV values of GTV/CTV were 3.50/1.41, which were close to the ground-truth values of 3.57/1.51. In 2D-based gamma tests, the average passing rate was 92.1% using 5%/10 mm criteria, which was improved to 95.9%/93.2% when focusing on GTV/CTV regions. 3D gamma test passing rates were 98.7% using 5%/10 mm criteria, and the corresponding GTV/CTV results were 99.8%/99.4%. Conclusion The reported results suggest that the developed AI agent DDD-PIOP successfully predicted 18FDG-PET image outcomes with high quantitative accuracy. The generated voxel-based image outcome predictions could be used for treatment planning optimization prior to radiation delivery for the best individual-based outcome.
Collapse
Affiliation(s)
- Chunhao Wang
- Department of Radiation Oncology, Duke University Medical Center, Durham, CA, United States
| | - Chenyang Liu
- Medical Physics Graduate Program, Duke Kunshan University, Kunshan, China
| | - Yushi Chang
- Department of Radiation Oncology, Duke University Medical Center, Durham, CA, United States
| | - Kyle Lafata
- Department of Radiation Oncology, Duke University Medical Center, Durham, CA, United States
| | - Yunfeng Cui
- Department of Radiation Oncology, Duke University Medical Center, Durham, CA, United States
| | - Jiahan Zhang
- Department of Radiation Oncology, Duke University Medical Center, Durham, CA, United States
| | - Yang Sheng
- Department of Radiation Oncology, Duke University Medical Center, Durham, CA, United States
| | - Yvonne Mowery
- Department of Radiation Oncology, Duke University Medical Center, Durham, CA, United States
| | - David Brizel
- Department of Radiation Oncology, Duke University Medical Center, Durham, CA, United States
| | - Fang-Fang Yin
- Department of Radiation Oncology, Duke University Medical Center, Durham, CA, United States.,Medical Physics Graduate Program, Duke Kunshan University, Kunshan, China
| |
Collapse
|
4
|
O'Keeffe AG, Ambler G, Barber JA. Sample size calculations based on a difference in medians for positively skewed outcomes in health care studies. BMC Med Res Methodol 2017; 17:157. [PMID: 29197347 PMCID: PMC5712177 DOI: 10.1186/s12874-017-0426-1] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2017] [Accepted: 11/14/2017] [Indexed: 12/03/2022] Open
Abstract
Background In healthcare research, outcomes with skewed probability distributions are common. Sample size calculations for such outcomes are typically based on estimates on a transformed scale (e.g. log) which may sometimes be difficult to obtain. In contrast, estimates of median and variance on the untransformed scale are generally easier to pre-specify. The aim of this paper is to describe how to calculate a sample size for a two group comparison of interest based on median and untransformed variance estimates for log-normal outcome data. Methods A log-normal distribution for outcome data is assumed and a sample size calculation approach for a two-sample t-test that compares log-transformed outcome data is demonstrated where the change of interest is specified as difference in median values on the untransformed scale. A simulation study is used to compare the method with a non-parametric alternative (Mann-Whitney U test) in a variety of scenarios and the method is applied to a real example in neurosurgery. Results The method attained a nominal power value in simulation studies and was favourable in comparison to a Mann-Whitney U test and a two-sample t-test of untransformed outcomes. In addition, the method can be adjusted and used in some situations where the outcome distribution is not strictly log-normal. Conclusions We recommend the use of this sample size calculation approach for outcome data that are expected to be positively skewed and where a two group comparison on a log-transformed scale is planned. An advantage of this method over usual calculations based on estimates on the log-transformed scale is that it allows clinical efficacy to be specified as a difference in medians and requires a variance estimate on the untransformed scale. Such estimates are often easier to obtain and more interpretable than those for log-transformed outcomes. Electronic supplementary material The online version of this article (doi:10.1186/s12874-017-0426-1) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Aidan G O'Keeffe
- Department of Statistical Science, University College London, Gower St., London, WC1E 6BT, UK. a.o'
| | - Gareth Ambler
- Department of Statistical Science, University College London, Gower St., London, WC1E 6BT, UK
| | - Julie A Barber
- Department of Statistical Science, University College London, Gower St., London, WC1E 6BT, UK
| |
Collapse
|
5
|
Chen J, Yang J, Sun X, Wang Z, Cheng X, Lu W, Cai X, Hu C, Shen X, Cao P. Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q. Sci Rep 2017; 7:16458. [PMID: 29184081 PMCID: PMC5705638 DOI: 10.1038/s41598-017-16427-w] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2017] [Accepted: 11/08/2017] [Indexed: 01/08/2023] Open
Abstract
Neomorphic mutation R140Q in the metabolic enzyme isocitrate dehydrogenase 2 (IDH2) is found to be a driver mutation in cancers. Recent studies revealed that allosteric inhibitors could selectively inhibit IDH2/R140Q and induce differentiation of TF-1 erythroleukemia and primary human AML cells. However, the allosteric inhibition mechanism is not very clear. Here, we report the results from computational studies that AGI-6780 binds tightly with the divalent cation binding helices at the homodimer interface and prevents the transition of IDH2/R140Q homodimer to a closed conformation that is required for catalysis, resulting in the decrease of the binding free energy of NADPHs. If the allosteric inhibitor is removed, the original open catalytic center of IDH2/R140Q will gradually reorganize to a quasi-closed conformation and the enzymatic activity might recover. Unlike IDH2/R140Q, AGI-6780 locks one monomer of the wild-type IDH2 in an inactive open conformation and the other in a half-closed conformation, which can be used to explain the selectivity of AGI-6780. Our results suggest that conformational changes are the primary contributors to the inhibitory potency of the allosteric inhibitor. Our study will also facilitate the understanding of the inhibitory and selective mechanisms of AG-221 (a promising allosteric inhibitor that has been approved by FDA) for mutant IDH2.
Collapse
Affiliation(s)
- Jiao Chen
- Key Laboratory of Drug Targets and Drug Leads for Degenerative Diseases, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.,Laboratory of Cellular and Molecular Biology, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, Jiangsu, China
| | - Jie Yang
- Key Laboratory of Drug Targets and Drug Leads for Degenerative Diseases, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.,Laboratory of Cellular and Molecular Biology, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, Jiangsu, China
| | - Xianqiang Sun
- Pharmaceutical Research Center, School of pharmacy, Guangzhou Medical University, 195 Dongfengxi Road, Guangzhou, China.,Division of Theoretical Chemistry and Biology, School of Biotechnology, KTH Royal Institute of Technology, S-106 91, Stockholm, Sweden
| | - Zhongming Wang
- Key Laboratory of Drug Targets and Drug Leads for Degenerative Diseases, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.,Laboratory of Cellular and Molecular Biology, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, Jiangsu, China
| | - Xiaolan Cheng
- Key Laboratory of Drug Targets and Drug Leads for Degenerative Diseases, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.,Laboratory of Cellular and Molecular Biology, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, Jiangsu, China
| | - Wuguang Lu
- Key Laboratory of Drug Targets and Drug Leads for Degenerative Diseases, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.,Laboratory of Cellular and Molecular Biology, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, Jiangsu, China
| | - Xueting Cai
- Key Laboratory of Drug Targets and Drug Leads for Degenerative Diseases, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.,Laboratory of Cellular and Molecular Biology, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, Jiangsu, China
| | - Chunping Hu
- Key Laboratory of Drug Targets and Drug Leads for Degenerative Diseases, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.,Laboratory of Cellular and Molecular Biology, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, Jiangsu, China
| | - Xu Shen
- Key Laboratory of Drug Targets and Drug Leads for Degenerative Diseases, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
| | - Peng Cao
- Key Laboratory of Drug Targets and Drug Leads for Degenerative Diseases, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China. .,Laboratory of Cellular and Molecular Biology, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, Jiangsu, China.
| |
Collapse
|